Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL30047029 | 0.97 | NOTUM (0.70) | NOTUMRAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL1544128 | 0.85 | NOTUM (1.00) | NOTUMRAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL1233832 | 0.84 | NOTUM (0.66) | NOTUMRAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL4041589 | 0.82 | NOTUM (0.51) | NOTUMRAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL1844414 | 0.82 | NOTUM (0.53) | NOTUMRAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL3955619 | 0.82 | NOTUM (0.51) | NOTUMRAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL28319063 | 0.82 | NOTUM (0.64) | NOTUMRAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL11804748 | 0.82 | NOTUM (0.64) | NOTUMRAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL27163705 | 0.82 | NOTUM (0.64) | NOTUMRAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL4041989 | 0.79 | NOTUM (0.48) | NOTUMRAB9ASMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022227015-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232333-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-2027128-A2 | FUSED HETEROCYLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | Astra Zeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| EP-1919901-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007130825-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007021573-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | NOTUM 3162/4885RAB9A 3769/4885SMN1; SMN2 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.